Correlation Engine 2.0
Clear Search sequence regions

Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression, particularly in patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression. However, MAOIs are not supported as first-line treatments due to safety and tolerability concerns and the need for dietary restrictions; instead, current guidelines recommend MAOIs as third-, fourth-, or fifth-line treatments. However, a newer, transdermal MAOI formulation limits the need for dietary restrictions and has fewer sexual and metabolic effects than some of the newer antidepressants. © Copyright 2012 Physicians Postgraduate Press, Inc.


Michael E Thase. MAOIs and depression treatment guidelines. The Journal of clinical psychiatry. 2012 Jul;73(7):e24

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 22901357

View Full Text